Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

22nd Century to Speak at Global Tobacco & Nicotine Forum

22nd Century Group,Inc.
Posted on: 13 Sep 17

22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that officials from the Global Tobacco & Nicotine Forum (GTNF) have invited the Company’s Chief Executive Officer, Henry Sicignano, III, to participate on a GTNF panel entitled “Future Next Generation Products” on September 14, 2017 in New York City.

The Global Tobacco & Nicotine Forum is the world’s foremost exchange of ideas and information for tobacco technologies and products. Attendees to the forum include public health advocates, policymakers, scientists, and international tobacco industry executives. Visit www.gtnf-2017.com for more on GTNF. Also speaking at this year’s forum are:

Mitch Zeller, Director, US Food and Drug Administration’s Center for Tobacco Products. Together with FDA Commissioner, Dr. Scott Gottlieb, in August 2017, Mr. Zeller, released an article entitled, “A Nicotine-Focused Framework of Public Health.” Published in The New England Journal of Medicine (NEJM), the article spells out the FDA’s regulatory authority for mandating non-addictive levels of nicotine in combustible cigarettes.

Dr. Dorothy Hatsukami, Forster Family Chair in Cancer Prevention; Associate Director, Masonic Cancer Center; and Professor of Psychiatry, University of Minnesota. In 2016, together with two other prominent scientists, Dr. Dorothy Hatsukami wrote in Tobacco Control that failure to act on the World Health Organization (WHO) recommendation of mandating nicotine reductions in cigarettes to non-addictive levels could lead to the loss of millions of lives.

Dr. Michael Cummings, Professor, Medical University of South Carolina Department of Psychiatry & Behavioral Sciences; and Co-Director, Tobacco Policy and Control Program at Hollings Cancer Center. As an expert in tobacco policy, Dr. Cummings is often called upon to guide global tobacco control policy initiatives around the world. Earlier in 2017, Dr. Cummings gave the keynote address at 22nd Century’s Annual Meeting of Stockholders.

“Since the FDA announced its intention to mandate that all cigarettes have very low, non-addictive levels of nicotine, the public health community has focused much of its attention on 22nd Century,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “We look forward to working together with scientists and policymakers to make Very Low Nicotine cigarettes a public health reality in the United States and around the world.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on genetic engineering and plant breeding which allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in cannabis is to develop proprietary hemp/cannabis strains for important new medicines and agricultural crops. Visit www.xxiicentury.com and www.botanicalgenetics.comfor more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 8, 2017, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170913005828/en/

Business Wire
www.businesswire.com

Last updated on: 13/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.